Novacyt Akcija

Novacyt EV/FCF

Vrijednost EV/FCF (Вредност предузећа према слободном готовинском току) od Novacyt (ALNOV.PA) na dan 11. авг 2026. je -0,55. Prethodne godine, EV/FCF (Вредност предузећа према слободном готовинском току) je bio 0,18 — promjena od -416,08% (niži).

EV/FCF

-0,55

YoY

-416,08%

Zadnja ažuriranja:

EV/FCF (Вредност предузећа према слободном готовинском току) od Novacyt je 2026 -0,55 . EV/FCF (Вредност предузећа према слободном готовинском току) od Novacyt je bio 2025 0,18 . Pad je time -416,08% niži u odnosu na prethodnu godinu.
Access this data via the Eulerpool API

Novacyt Анализа акција

Šta radi Novacyt? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt je jedna od najpopularnijih kompanija na Eulerpool.

Često postavljena pitanja o akciji Novacyt

EV/FCF (Вредност предузећа према слободном готовинском току) kompanije Novacyt iznosi -0,55 u 2026. godini.

EV/FCF (Вредност предузећа према слободном готовинском току) od Novacyt se promijenio sa 0,18 na -0,55, što predstavlja promjenu od -416,08%. Vrijednost je niži nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj EV/FCF (Вредност предузећа према слободном готовинском току) Novacyt od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

Однос EV/FCF мери вредност предузећа у односу на слободан готовински ток и обухвата праву генерисање готовине пословања.

Da biste proverili EV/FCF (Вредност предузећа према слободном готовинском току)'s, bitno je da ga uporedite sa konkurentima u istoj industriji i sektoru. Na Eulopoolu, možete pronaći direktna upoređivanja industrije za EV/FCF (Вредност предузећа према слободном готовинском току).

Dobar varira u zavisnosti od industrije i faze razvoja preduzeća. Na Eulopoolu, možete porediti EV/FCF (Вредност предузећа према слободном готовинском току)'s Novacyt sa sličnim preduzećima u sektoru i prosekom industrije da biste proverili da li je atraktivan.

Access this data via the Eulerpool API

Вредновање — Novacyt

Sve ključne metrike — Novacyt

Раст